Immunocore is the world’s leading T cell receptor (TCR) company, a global biotech striving to transform medical practice in the most challenging disease areas. The Company is focused on delivering first-in-class biological therapies to patients, using its highly innovative soluble TCR platform, and ImmTAC® molecules, a new class of precision-engineered drugs with ultra-high affinity for intracellular cancer targets. ImmTAC molecules naturally recognise cancer cells and cause their destruction through re-directing and activating the patient’s own immune system. This novel class of immunotherapy has the potential to treat a broad spectrum of diseases with high unmet medical need, not only cancers, but also infectious diseases and autoimmune diseases.
In addition to a well-established pipeline of wholly-owned programmes, Immunocore’s world-leading science and strong IP position has led to discovery collaborations with major pharmaceutical companies including Genentech, GlaxoSmithKline and MedImmune, the biologics division of AstraZeneca, as well as a co-discovery and co-development partnership with Lilly. The Company is also conducting a combination clinical trial with IMCgp100 and two of MedImmune’s checkpoint immuno-therapies, durvalumab and tremelimumab.
Immunocore, headquartered near Oxford, UK and Eli Lilly and Company, RTW Investments, Baker Brothers, Fidelity Management & Research Company as well as other private shareholders.